{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T02:39:42Z","timestamp":1786502382743,"version":"build-2736575974"},"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gates Foundation","award":["INV-007368 and INV-036842"],"award-info":[{"award-number":["INV-007368 and INV-036842"]}]},{"name":"Gates Foundation","award":["INV-048656"],"award-info":[{"award-number":["INV-048656"]}]},{"name":"NIH","award":["AI068619, UM1 AI068617, UM1 AI068613, UM1 AI068614, UM1 AI068635, UM1 AI068618"],"award-info":[{"award-number":["AI068619, UM1 AI068617, UM1 AI068613, UM1 AI068614, UM1 AI068635, UM1 AI068618"]}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>Although a protective HIV-1 vaccine has not yet been realized, significant progress has been made in vaccine designs that trigger B cell lineages with potential to produce broadly neutralizing antibodies (bnAbs). Advancing these strategies by optimizing vaccine boosting regimens requires early detection of maturing antibodies with neutralizing activity against native envelope glycoprotein (Env) trimers and streamlined strategies to identify antibodies as they begin to manifest desired levels of breadth and potency. Thus, we designed three types of pseudovirus screening panels based on Envs of contemporary HIV-1 isolates to facilitate detection of bnAb lineages that are on favorable trajectories during a vaccination course. The panels were selected from Tier 2 Transmitted Founder Lineage (TFL) HIV-1 Envs from placebo participants in the Antibody Mediated Prevention (AMP) efficacy trials. Using 15 bnAbs to evaluate the neutralization sensitivity of the viruses, we selected 8-member bnAb class-specific panels most sensitive to bnAbs representing their class: V2-apex, V3-glycan, CD4-receptor binding site (CD4bs), Membrane-Proximal External Region (MPER), or fusion peptide (FP). Next, we combined the most sensitive viruses among the class-specific panels to create a 12-virus panel to enable optimal detection of low-titer bnAb activity across epitope specificities. Finally, as HIV-1 continues to evolve greater levels of antigenic diversity and as current global pseudoviruses bnAb panels rely on viruses collected more than twenty years ago, we showed the importance of using contemporary viral panels to assess bnAb breadth and potency and designed a 12-virus panel representative of the spectrum neutralization profiles among AMP placebo viruses. We characterized pseudoviruses bearing each selected Env using standardized human sera to confirm their Tier 2 status and biological relevance. These updated panels enable sensitive screening of neutralization activity in vaccine studies and can also provide a realistic assessment of the expected breadth and potency of maturing responses against contemporary HIV-1 Envs.<\/jats:p>","DOI":"10.1371\/journal.ppat.1013739","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T17:20:39Z","timestamp":1776964839000},"page":"e1013739","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Contemporary HIV-1 envelope pseudovirus panels for detecting and assessing B cell lineages with broadly neutralizing antibody potential"],"prefix":"10.1371","volume":"22","author":[{"given":"Bette","family":"Korber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nonhlanhla N.","family":"Mkhize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Domin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haili","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Theiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kshitij","family":"Wagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny L.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James I.","family":"Mullins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole A.","family":"Doria-Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2968-1033","authenticated-orcid":true,"given":"Elena E.","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"issue":"21","key":"ppat.1013739.ref001","doi-asserted-by":"crossref","first-page":"12623","DOI":"10.1128\/JVI.01705-14","article-title":"Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies","volume":"88","author":"P Hraber","year":"2014","journal-title":"J Virol"},{"issue":"6","key":"ppat.1013739.ref002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011469","article-title":"Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials","volume":"19","author":"NN Mkhize","year":"2023","journal-title":"PLoS Pathog"},{"issue":"7","key":"ppat.1013739.ref003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005742","article-title":"Features of recently transmitted HIV-1 clade C viruses that impact antibody recognition: implications for active and passive immunization","volume":"12","author":"C Rademeyer","year":"2016","journal-title":"PLoS Pathog"},{"issue":"6","key":"ppat.1013739.ref004","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00008-25","article-title":"Distinct region-specific neutralization profiles of contemporary HIV-1 clade C against best-in-class broadly neutralizing antibodies","volume":"99","author":"J Sutar","year":"2025","journal-title":"J Virol"},{"issue":"12","key":"ppat.1013739.ref005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011780","article-title":"Evolution of HIV-1 envelope towards reduced neutralization sensitivity, as demonstrated by contemporary HIV-1 subtype B from the United States","volume":"19","author":"L Wieczorek","year":"2023","journal-title":"PLoS Pathog"},{"issue":"6","key":"ppat.1013739.ref006","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1128\/JVI.06745-11","article-title":"HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes","volume":"86","author":"NA Doria-Rose","year":"2012","journal-title":"J Virol"},{"key":"ppat.1013739.ref007","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv404","article-title":"CATNAP: a tool to compile, analyze and tally neutralizing antibody panels","volume":"43","author":"H Yoon","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"ppat.1013739.ref008","doi-asserted-by":"crossref","first-page":"7593","DOI":"10.1038\/s41467-023-42098-5","article-title":"Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site","volume":"14","author":"BB Banach","year":"2023","journal-title":"Nat Commun"},{"issue":"25","key":"ppat.1013739.ref009","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2024.10.003","article-title":"Potent and broad HIV-1 neutralization in fusion peptide-primed SHIV-infected macaques","volume":"187","author":"H Wang","year":"2024","journal-title":"Cell"},{"issue":"1","key":"ppat.1013739.ref010","doi-asserted-by":"crossref","first-page":"2165390","DOI":"10.1080\/19420862.2023.2165390","article-title":"Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency","volume":"15","author":"B Zhang","year":"2023","journal-title":"MAbs"},{"issue":"2","key":"ppat.1013739.ref011","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/COH.0000000000000442","article-title":"Neutralization tiers of HIV-1","volume":"13","author":"DC Montefiori","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"ppat.1013739.ref012","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.31805","article-title":"A single, continuous metric to define tiered serum neutralization potency against HIV","volume":"7","author":"P Hraber","year":"2018","journal-title":"Elife"},{"issue":"3","key":"ppat.1013739.ref013","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/infdis\/jis367","article-title":"Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials","volume":"206","author":"DC Montefiori","year":"2012","journal-title":"J Infect Dis"},{"issue":"3","key":"ppat.1013739.ref014","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1128\/JVI.02108-09","article-title":"Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies","volume":"84","author":"MS Seaman","year":"2010","journal-title":"J Virol"},{"issue":"5","key":"ppat.1013739.ref015","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1128\/JVI.02853-13","article-title":"Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies","volume":"88","author":"A deCamp","year":"2014","journal-title":"J Virol"},{"issue":"19","key":"ppat.1013739.ref016","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00991-17","article-title":"Panels of HIV-1 subtype C Env reference strains for standardized neutralization assessments","volume":"91","author":"P Hraber","year":"2017","journal-title":"J Virol"},{"issue":"8","key":"ppat.1013739.ref017","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1128\/JVI.02660-07","article-title":"Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing","volume":"82","author":"JF Salazar-Gonzalez","year":"2008","journal-title":"J Virol"},{"issue":"1","key":"ppat.1013739.ref018","doi-asserted-by":"crossref","DOI":"10.1093\/ve\/veae019","article-title":"Optimized SMRT-UMI protocol produces highly accurate sequence datasets from diverse populations-Application to HIV-1 quasispecies","volume":"10","author":"DH Westfall","year":"2024","journal-title":"Virus Evol"},{"issue":"11","key":"ppat.1013739.ref019","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition","volume":"384","author":"L Corey","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"ppat.1013739.ref020","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/s41591-022-01953-6","article-title":"Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition","volume":"28","author":"PB Gilbert","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"ppat.1013739.ref021","doi-asserted-by":"crossref","first-page":"8299","DOI":"10.1038\/s41467-023-43384-y","article-title":"High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials","volume":"14","author":"DB Reeves","year":"2023","journal-title":"Nat Commun"},{"issue":"3","key":"ppat.1013739.ref022","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41577-022-00753-w","article-title":"Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies","volume":"23","author":"BF Haynes","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"ppat.1013739.ref023","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03370-22","article-title":"A germline-targeting chimpanzee SIV envelope glycoprotein elicits a new class of V2-apex directed cross-neutralizing antibodies","volume":"14","author":"F Bibollet-Ruche","year":"2023","journal-title":"mBio"},{"issue":"4","key":"ppat.1013739.ref024","doi-asserted-by":"crossref","first-page":"101003","DOI":"10.1016\/j.xcrm.2023.101003","article-title":"Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions","volume":"4","author":"TG Caniels","year":"2023","journal-title":"Cell Rep Med"},{"issue":"697","key":"ppat.1013739.ref025","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adf3309","article-title":"A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses","volume":"15","author":"KW Cohen","year":"2023","journal-title":"Sci Transl Med"},{"issue":"621","key":"ppat.1013739.ref026","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abk1533","article-title":"Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env","volume":"13","author":"A Escolano","year":"2021","journal-title":"Sci Transl Med"},{"issue":"6470","key":"ppat.1013739.ref027","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay7199","article-title":"Targeted selection of HIV-specific antibody mutations by engineering B cell maturation","volume":"366","author":"KO Saunders","year":"2019","journal-title":"Science"},{"key":"ppat.1013739.ref028","article-title":"Vaccine induction of heterologous HIV-1 neutralizing antibody B cell lineages in humans","author":"WB Williams","year":"2023","journal-title":"medRxiv"},{"issue":"5","key":"ppat.1013739.ref029","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3390\/pharmaceutics16050594","article-title":"Impact of LS mutation on pharmacokinetics of preventive HIV broadly neutralizing monoclonal antibodies: a cross-protocol analysis of 16 clinical trials in people without HIV","volume":"16","author":"BT Mayer","year":"2024","journal-title":"Pharmaceutics"},{"issue":"6","key":"ppat.1013739.ref030","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1084\/jem.20130221","article-title":"Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies","volume":"210","author":"R Diskin","year":"2013","journal-title":"J Exp Med"},{"issue":"7","key":"ppat.1013739.ref031","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.cell.2016.05.024","article-title":"Engineered bispecific antibodies with exquisite HIV-1-neutralizing activity","volume":"165","author":"Y Huang","year":"2016","journal-title":"Cell"},{"issue":"47","key":"ppat.1013739.ref032","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1217207109","article-title":"Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies","volume":"109","author":"H Mouquet","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"ppat.1013739.ref033","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2019.04.014","article-title":"Broad and potent neutralizing antibodies recognize the silent face of the HIV envelope","volume":"50","author":"T Schoofs","year":"2019","journal-title":"Immunity"},{"issue":"2","key":"ppat.1013739.ref034","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.chom.2019.07.016","article-title":"HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design","volume":"26","author":"CA Bricault","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ppat.1013739.ref035","article-title":"Rapid loss of activity but not serum concentration in a passive infusion clinical trial of an HIV neutralizing antibody","author":"S Mahomed","year":"2025","journal-title":"medRxiv"},{"key":"ppat.1013739.ref036","article-title":"Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV-1 V2 apex broadly neutralizing antibody development","author":"R Habib","year":"2025","journal-title":"bioRxiv"},{"issue":"4","key":"ppat.1013739.ref037","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2308942121","article-title":"Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features","volume":"121","author":"M Juraska","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ppat.1013739.ref038","first-page":"2825","article-title":"Scikit-learn: machine learning in Python","volume":"12","author":"F Pedregosa","year":"2011","journal-title":"J Mach Learn Res"},{"issue":"1","key":"ppat.1013739.ref039","doi-asserted-by":"crossref","first-page":"17876","DOI":"10.1038\/s41598-022-22435-2","article-title":"Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life","volume":"12","author":"B Zhang","year":"2022","journal-title":"Sci Rep"},{"key":"ppat.1013739.ref040","article-title":"Optimized SMRT-UMI protocol produces highly accurate sequence datasets from diverse populations - application to HIV-1 quasispecies","author":"DH Westfall","year":"2023","journal-title":"bioRxiv"},{"issue":"7","key":"ppat.1013739.ref041","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.chom.2021.05.012","article-title":"HIV-1 and SARS-CoV-2: patterns in the evolution of two pandemic pathogens","volume":"29","author":"W Fischer","year":"2021","journal-title":"Cell Host Microbe."},{"issue":"5","key":"ppat.1013739.ref042","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3390\/v11050482","article-title":"Limited sustained local transmission of HIV-1 CRF01_AE in New South Wales, Australia","volume":"11","author":"F Di Giallonardo","year":"2019","journal-title":"Viruses"},{"issue":"10","key":"ppat.1013739.ref043","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1093\/cid\/ciad058","article-title":"Circulation of human immunodeficiency virus 1 A6 variant in the eastern border of the European Union-dynamics of the virus transmissions between Poland and Ukraine","volume":"76","author":"K Serwin","year":"2023","journal-title":"Clin Infect Dis"},{"key":"ppat.1013739.ref044","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.meegid.2016.06.033","article-title":"Molecular epidemiology of HIV-1 infection in Europe: an overview","volume":"46","author":"A Beloukas","year":"2016","journal-title":"Infect Genet Evol"},{"issue":"3","key":"ppat.1013739.ref045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009490","article-title":"FastTree 2--approximately maximum-likelihood trees for large alignments","volume":"5","author":"MN Price","year":"2010","journal-title":"PLoS One"},{"issue":"3","key":"ppat.1013739.ref046","first-page":"275","article-title":"The rapid generation of mutation data matrices from protein sequences","volume":"8","author":"DT Jones","year":"1992","journal-title":"Comput Appl Biosci"},{"key":"ppat.1013739.ref047","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/978-1-59745-170-3_26","article-title":"Measuring HIV neutralization in a luciferase reporter gene assay","volume":"485","author":"DC Montefiori","year":"2009","journal-title":"Methods Mol Biol"},{"key":"ppat.1013739.ref048","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"M Sarzotti-Kelsoe","year":"2014","journal-title":"J Immunol Methods"},{"issue":"16","key":"ppat.1013739.ref049","doi-asserted-by":"crossref","first-page":"10108","DOI":"10.1128\/JVI.79.16.10108-10125.2005","article-title":"Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies","volume":"79","author":"M Li","year":"2005","journal-title":"J Virol"},{"key":"ppat.1013739.ref050","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jim.2011.09.007","article-title":"Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells","volume":"375","author":"CA Todd","year":"2012","journal-title":"J Immunol Methods"},{"issue":"18","key":"ppat.1013739.ref051","doi-asserted-by":"crossref","first-page":"9035","DOI":"10.1128\/JVI.76.18.9035-9045.2002","article-title":"Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades","volume":"76","author":"MK Gorny","year":"2002","journal-title":"J Virol."},{"issue":"5","key":"ppat.1013739.ref052","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1128\/JVI.78.5.2394-2404.2004","article-title":"The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope","volume":"78","author":"MK Gorny","year":"2004","journal-title":"J Virol."},{"issue":"14","key":"ppat.1013739.ref053","doi-asserted-by":"crossref","first-page":"6865","DOI":"10.1128\/JVI.02202-05","article-title":"Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1","volume":"80","author":"MK Gorny","year":"2006","journal-title":"J Virol."},{"issue":"5","key":"ppat.1013739.ref054","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.molimm.2008.09.005","article-title":"Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.","volume":"46","author":"MK Gorny","year":"2009","journal-title":"Mol Immunol."},{"issue":"8","key":"ppat.1013739.ref055","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1089\/aid.1992.8.1395","article-title":"Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains","volume":"8","author":"A Buchbinder","year":"1992","journal-title":"AIDS Res Hum Retroviruses."},{"issue":"10","key":"ppat.1013739.ref056","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.4049\/jimmunol.159.10.5114","article-title":"Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity","volume":"159","author":"MK Gorny","year":"1997","journal-title":"J Immunol."},{"issue":"6","key":"ppat.1013739.ref057","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1128\/jvi.68.6.4001-4008.1994","article-title":"Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies","volume":"68","author":"S Laal","year":"1994","journal-title":"J Virol."},{"issue":"6","key":"ppat.1013739.ref058","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1128\/jvi.69.6.3807-3815.1995","article-title":"Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry","volume":"69","author":"S Zolla-Pazner","year":"1995","journal-title":"J Virol."},{"issue":"12","key":"ppat.1013739.ref059","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.4049\/jimmunol.146.12.4325","article-title":"An IgG human monoclonal antibody that reacts with HIV-1\/GP120, inhibits virus binding to cells, and neutralizes infection","volume":"146","author":"MR Posner","year":"1991","journal-title":"J Immunol."}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1013739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T17:20:49Z","timestamp":1776964849000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1013739"}},"subtitle":[],"editor":[{"given":"Guido","family":"Silvestri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":59,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1013739","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]}}}